請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72877
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 黃明經(Ming-Jing Hwang) | |
dc.contributor.author | Chih-Han Huang | en |
dc.contributor.author | 黃之瀚 | zh_TW |
dc.date.accessioned | 2021-06-17T07:08:56Z | - |
dc.date.available | 2019-07-25 | |
dc.date.copyright | 2019-07-25 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-07-23 | |
dc.identifier.citation | 1. Kuhn, Michael, Ivica Letunic, Lars Juhl Jensen, and Peer Bork, The SIDER database of drugs and side effects. Nucleic acids research, 2015. 44(D1): p. D1075-D1079.
2. Gad, S.C., Drug Safety Evaluation. 2003: Wiley. 3. Tsopelas, Fotios, Constantinos Giaginis, and Anna Tsantili-Kakoulidou, Lipophilicity and biomimetic properties to support drug discovery. Expert opinion on drug discovery, 2017. 12(9): p. 885-896. 4. Perioli, Luana and Cinzia Pagano, Inorganic matrices: an answer to low drug solubility problem. Expert opinion on drug delivery, 2012. 9(12): p. 1559-1572. 5. Reynolds, Charles H, Ligand efficiency metrics: why all the fuss? Future medicinal chemistry, 2015. 7(11): p. 1363-1365. 6. Hopkins, Andrew L, Colin R Groom, and Alexander Alex, Ligand efficiency: a useful metric for lead selection. Drug discovery today, 2004. 9(10): p. 430-431. 7. Smith, Dennis A and R Scott Obach, Metabolites: have we MIST out the importance of structure and physicochemistry? Bioanalysis, 2010. 2(7): p. 1223-1233. 8. Ghose, Arup K, Vellarkad N Viswanadhan, and John J Wendoloski, A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. Journal of combinatorial chemistry, 1999. 1(1): p. 55-68. 9. Ghose, Arup K and Gordon M Crippen, Atomic physicochemical parameters for three-dimensional-structure-directed quantitative structure-activity relationships. 2. Modeling dispersive and hydrophobic interactions. Journal of chemical information and computer sciences, 1987. 27(1): p. 21-35. 10. Sixt, Stefan, Joachim Altschuh, and Rainer Brüggemann, Quantitative structure-toxicity relationships for 80 chlorinated compounds using quantum chemical descriptors. Chemosphere, 1995. 30(12): p. 2397-2414. 11. Dong, Yuxiang, Xiaofang Wang, Sriraghavan Kamaraj, Vivek J Bulbule, Francis Ck Chiu, Jacques Chollet, Manickam Dhanasekaran, Christopher D Hein, Petros Papastogiannidis, and Julia Morizzi, Structure–Activity Relationship of the Antimalarial Ozonide Artefenomel (OZ439). Journal of medicinal chemistry, 2017. 60(7): p. 2654-2668. 12. Muggia, F., New Drugs for Malignancy, An Issue of Hematology/Oncology Clinics of North America - E-Book. 2012: Elsevier Health Sciences. 13. Veber, Daniel F, Stephen R Johnson, Hung-Yuan Cheng, Brian R Smith, Keith W Ward, and Kenneth D Kopple, Molecular properties that influence the oral bioavailability of drug candidates. Journal of medicinal chemistry, 2002. 45(12): p. 2615-2623. 14. Shippee-Rice, Raelene V, Susan Fetzer, Jennifer V Long, and Alexandra Armitage, Gerioperative nursing care: principles and practices of surgical care for the older adult. 2011: Springer Publishing Company. 15. Di, L. and E.H. Kerns, Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization. 2010: Elsevier Science. 16. Ritchie, Timothy J and Simon Jf Macdonald, The impact of aromatic ring count on compound developability–are too many aromatic rings a liability in drug design? Drug discovery today, 2009. 14(21-22): p. 1011-1020. 17. Lipinski, Christopher A, Franco Lombardo, Beryl W Dominy, and Paul J Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced drug delivery reviews, 1997. 23(1-3): p. 3-25. 18. Oprea, Tudor I, Property distribution of drug-related chemical databases. Journal of computer-aided molecular design, 2000. 14(3): p. 251-264. 19. Samuel, Al, Some studies in machine learning using the game of checkers. Reprinted in EA Feigenbaum & J. Feldman (Eds.)(1963). Computers and thought. 1959, McGraw-Hill. 20. Breiman, Leo, Random forests. Machine learning, 2001. 45(1): p. 5-32. 21. Boroujerdi, M., Pharmacokinetics and Toxicokinetics. 2015: CRC Press. 22. Makita, Naomasa, Minoru Horie, Takeshi Nakamura, Tomohiko Ai, Koji Sasaki, Hisataka Yokoi, Masayuki Sakurai, Ichiro Sakuma, Hideo Otani, and Hirofumi Sawa, Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation, 2002. 106(10): p. 1269-1274. 23. Morgan, Steve, Paul Grootendorst, Joel Lexchin, Colleen Cunningham, and Devon Greyson, The cost of drug development: a systematic review. Health policy, 2011. 100(1): p. 4-17. 24. Angsutararux, Paweorn, Sudjit Luanpitpong, and Surapol Issaragrisil, Chemotherapy-induced cardiotoxicity: overview of the roles of oxidative stress. Oxidative medicine and cellular longevity, 2015. 2015. 25. Klaassen, C., Casarett & Doull's Toxicology: The Basic Science of Poisons, Seventh Edition. 2007: Mcgraw-hill. 26. Blankesteijn, M. and R. Altara, Inflammation in Heart Failure. 2014: Elsevier Science. 27. Konopelski, Piotr and Marcin Ufnal, Electrocardiography in rats: a comparison to human. Physiological research, 2016. 65(5). 28. Acosta, D., Cardiovascular Toxicology. 2008: CRC Press. 29. Donnelly, Kevin B, Cardiac valvular pathology: comparative pathology and animal models of acquired cardiac valvular diseases. Toxicologic pathology, 2008. 36(2): p. 204-217. 30. Ewart, Lorna, Mike Aylott, Mark Deurinck, Mike Engwall, David J Gallacher, Helena Geys, Philip Jarvis, Haisong Ju, Derek Leishman, and Louise Leong, The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative. Toxicological Sciences, 2014. 142(2): p. 427-435. 31. Sahota, P.S., J.A. Popp, J.F. Hardisty, C. Gopinath, and P. Bouchard, Toxicologic Pathology: Nonclinical Safety Assessment, Second Edition. 2018: CRC Press. 32. Farraj, Aimen K, Mehdi S Hazari, and Wayne E Cascio, The utility of the small rodent electrocardiogram in toxicology. Toxicological sciences, 2011. 121(1): p. 11-30. 33. Silverman, R.B., The Organic Chemistry of Drug Design and Drug Action. 2004: Elsevier Science. 34. Antunes, Alexandra Mm, Ana La Godinho, Inês L Martins, M Conceiçao Oliveira, Ricardo A Gomes, Ana V Coelho, Frederick A Beland, and M Matilde Marques, Protein adducts as prospective biomarkers of nevirapine toxicity. Chemical research in toxicology, 2010. 23(11): p. 1714-1725. 35. Wong, Dairong, Miao Wang, Yan Cheng, and Garret A Fitzgerald, Cardiovascular hazard and non-steroidal anti-inflammatory drugs. Current opinion in pharmacology, 2005. 5(2): p. 204-210. 36. Begum, Tina, Tapash Chandra Ghosh, and Surajit Basak, Systematic analyses and prediction of human drug side effect associated proteins from the perspective of protein evolution. Genome biology and evolution, 2017. 9(2): p. 337-350. 37. Jiang, Yanping, Yizhou Li, Qifan Kuang, Ling Ye, Yiming Wu, Lijun Yang, and Menglong Li, Predicting putative adverse drug reaction related proteins based on network topological properties. Analytical Methods, 2014. 6(8): p. 2692-2698. 38. Wishart, David S, Yannick D Feunang, An C Guo, Elvis J Lo, Ana Marcu, Jason R Grant, Tanvir Sajed, Daniel Johnson, Carin Li, and Zinat Sayeeda, DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic acids research, 2017. 46(D1): p. D1074-D1082. 39. Géron, A., Hands-On Machine Learning with Scikit-Learn and TensorFlow: Concepts, Tools, and Techniques to Build Intelligent Systems. 2017: O'Reilly Media. 40. Strobl, Carolin, Anne-Laure Boulesteix, Thomas Kneib, Thomas Augustin, and Achim Zeileis, Conditional variable importance for random forests. BMC bioinformatics, 2008. 9(1): p. 307. 41. Pedregosa, Fabian, Gaël Varoquaux, Alexandre Gramfort, Vincent Michel, Bertrand Thirion, Olivier Grisel, Mathieu Blondel, Peter Prettenhofer, Ron Weiss, and Vincent Dubourg, Scikit-learn: Machine learning in Python. Journal of machine learning research, 2011. 12(Oct): p. 2825-2830. 42. Law, Vivian, Craig Knox, Yannick Djoumbou, Tim Jewison, An Chi Guo, Yifeng Liu, Adam Maciejewski, David Arndt, Michael Wilson, and Vanessa Neveu, DrugBank 4.0: shedding new light on drug metabolism. Nucleic acids research, 2013. 42(D1): p. D1091-D1097. 43. Kuhn, Michael, Monica Campillos, Ivica Letunic, Lars Juhl Jensen, and Peer Bork, A side effect resource to capture phenotypic effects of drugs. Molecular systems biology, 2010. 6(1): p. 343. 44. Isbister, Geoffrey K and Nick A Buckley, The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clinical neuropharmacology, 2005. 28(5): p. 205-214. 45. Blobaum, Anna L and Lawrence J Marnett, Structural and functional basis of cyclooxygenase inhibition. Journal of medicinal chemistry, 2007. 50(7): p. 1425-1441. 46. Bombardier, Claire, Loren Laine, Alise Reicin, Deborah Shapiro, Ruben Burgos-Vargas, Barry Davis, Richard Day, Marcos Bosi Ferraz, Christopher J Hawkey, and Marc C Hochberg, Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New England Journal of Medicine, 2000. 343(21): p. 1520-1528. 47. Nussmeier, Nancy A, Andrew A Whelton, Mark T Brown, Richard M Langford, Andreas Hoeft, Joel L Parlow, Steven W Boyce, and Kenneth M Verburg, Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. New England Journal of Medicine, 2005. 352(11): p. 1081-1091. 48. Sanguinetti, Michael C and Martin Tristani-Firouzi, hERG potassium channels and cardiac arrhythmia. Nature, 2006. 440(7083): p. 463. 49. Rothman, Richard B and Michael H Baumann, Therapeutic and adverse actions of serotonin transporter substrates. Pharmacology & therapeutics, 2002. 95(1): p. 73-88. 50. Gettins, Peter, Philip A Patston, and Marc Schapira, Structure and mechanism of action of serpins. Hematology/Oncology Clinics, 1992. 6(6): p. 1393-1408. 51. gren, A, B Wiman, V Stiller, P Lindmarker, M Sten‐Linder, A Carlsson, M Holmström, J Odeberg, and S Schulman, Evaluation of low PAI‐1 activity as a risk factor for hemorrhagic diathesis. Journal of Thrombosis and Haemostasis, 2006. 4(1): p. 201-208. 52. Vaughan, Douglas E, Bart M De Taeye, and Mesut Eren, PAI-1 antagonists: predictable indications and unconventional applications. Current drug targets, 2007. 8(9): p. 962-970. 53. Münz, Markus, Alexander Murr, Majk Kvesic, Doris Rau, Susanne Mangold, Stefan Pflanz, John Lumsden, Jörg Volkland, Jan Fagerberg, and Gert Riethmüller, Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer cell international, 2010. 10(1): p. 44. 54. Andersson, Y, O Engebraaten, S Juell, S Aamdal, P Brunsvig, Fodstad, and S Dueland, Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin. British journal of cancer, 2015. 113(11): p. 1548. 55. Bhave, Vishakha S, Shashikiran Donthamsetty, John R Latendresse, Levan Muskhelishvili, and Harihara M Mehendale, Secretory phospholipase A2 mediates progression of acute liver injury in the absence of sufficient cyclooxygenase-2. Toxicology and applied pharmacology, 2008. 228(2): p. 225-238. 56. Watkins, Paul, COMT inhibitors and liver toxicity. Neurology, 2000. 55(11 Suppl 4): p. S51-2; discussion S53-6. 57. Sykes, David A, Holly Moore, Lisa Stott, Nicholas Holliday, Jonathan A Javitch, J Robert Lane, and Steven J Charlton, Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D 2 receptors. Nature communications, 2017. 8(1): p. 763. 58. Ungerer, Martin, M Böhm, John S Elce, Elmj Erdmann, and Martin J Lohse, Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation, 1993. 87(2): p. 454-463. 59. Fosslien, Egil, Cardiovascular complications of non-steroidal anti-inflammatory drugs. Annals of Clinical & Laboratory Science, 2005. 35(4): p. 347-385. 60. Paavonen, Kristian J, Hugh Chapman, Päivi J Laitinen, Heidi Fodstad, Kirsi Piippo, Heikki Swan, Lauri Toivonen, Matti Viitasalo, Kimmo Kontula, and Michael Pasternack, Functional characterization of the common amino acid 897 polymorphism of the cardiac potassium channel KCNH2 (HERG). Cardiovascular research, 2003. 59(3): p. 603-611. 61. Perlis, Roy H, David Mischoulon, Jordan W Smoller, Yu-Jui Yvonne Wan, Stefania Lamon-Fava, Keh-Ming Lin, Jerrold F Rosenbaum, and Maurizio Fava, Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biological psychiatry, 2003. 54(9): p. 879-883. 62. De Haas, Esther C, Nynke Zwart, Coby Meijer, Albert Jh Suurmeijer, Karina Meijer, Henk‐Jan Guchelaar, Harald J Hoekstra, Flora E Van Leeuwen, Dirk Th Sleijfer, and H Marike Boezen, Association of PAI‐1 gene polymorphism with survival and chemotherapy‐related vascular toxicity in testicular cancer. Cancer, 2010. 116(24): p. 5628-5636. 63. Ross, Joy R, Julia Riley, Annie B Taegetmeyer, Hiroe Sato, Sophy Gretton, Roland M Du Bois, and Kenneth I Welsh, Genetic variation and response to morphine in cancer patients: catechol‐O‐methyltransferase and multidrug resistance‐1 gene polymorphisms are associated with central side effects. Cancer: Interdisciplinary International Journal of the American Cancer Society, 2008. 112(6): p. 1390-1403. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/72877 | - |
dc.description.abstract | 藥物設計的研發成本和時間消耗是藥廠的重大投資,但是藥物不良反應可能導致藥物在臨床試驗期間或藥物上市後被撤銷核准,造成藥廠財務上的重大損失。現今沒有論文直接研究已下市的藥物與目前仍在市場上的藥物之間的化學性質差異程度。了解下市藥物(withdrawn drugs;WDs)的相關因素及其不良反應將有助於臨床前毒性試驗。深究WDs與市場藥物(on market drugs;MDs)之間的性質分佈可為科學家們提供新概念,以避免開發在上市後或臨床試驗期間才被終止使用的藥物。
在本文中,我們系統地分析了WDs和MDs的化學特徵,結果使我們能夠提出「WD -like」和「MD -like」基團的化學性質範圍。使用前人建立的藥物設計規則(例如Rule of Five, Ghose Filter, and MDDR-Like Rule)辨認出WDs的效果也在本研究的範疇,我們並提出了新的藥物設計規則「Rule of on market drugs」。我們也開發了一種通過機器學習來預測WD和MD的新方法,還研究了WDs和MDs的蛋白質標的。為了探索蛋白質標的與藥物的不良反應之間的關係,我們研究了不良反應相關蛋白(adverse related proteins;ARPs)和非不良反應相關蛋白(non adverse related proteins;NARPs)的許多特徵。我們檢驗了這些功能在ARP和NARP之間是否存在顯著差異,並應用機器學習來分類ARPs和NARPs,評估了每個特徵對所得模型的重要性。本論文對WDs、MDs、ARPs和NARPs的研究使我們能夠為未來的藥物開發研究制定一些新指南,可避免或盡量減少藥物使用不良反應的風險。 | zh_TW |
dc.description.abstract | The financial cost and time consumption of drug design are tremendous, yet adverse effects can cause drugs to be withdrawn during clinical trials or after the drugs are on the market. There had been no report directly investigating to what extent the chemical properties between drugs that have been withdrawn and those that are currently on the market are different. Understanding the factors connecting withdrawn drugs (WDs) and their adverse effects would help in preclinical toxicity studies. Knowing the distribution of properties between WDs and on market drugs (MDs) may provide new concepts for scientists to avoid developing a drug that may be withdrawn from the market or during clinical trials. In the works presented in this thesis, we systemically analyzed the chemical features of WDs and MDs. The result allowed us to propose ranges of chemical properties for “WD -like” and “MD-like” groups. The performance of filtering out WDs using previously established rules for drugs design such as Rule of Five, Ghose Filter, and MDDR-Like Rule was investigated and a new rule of a drug design “Rule of on market drugs” was proposed. We then developed a novel method to predict WDs and MDs by machine learning. Protein targets of WDs and MDs were also investigated. To explore the relationship between protein targets and drug-induced adverse effects, many features of adverse effect related proteins (ARPs) and non adverse effect related proteins (NARPs) were studied. We examined whether these features were significantly different between ARPs and NARPs. Machine learning was applied to classify ARPs and NARPs. The importance of each feature for the resulting model was assessed. The present studies of WDs and MDs, and also of ARPs and NARPs, allow us to develop some new guidelines for future drug development research to avoid or minimize the risk of adverse effect. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T07:08:56Z (GMT). No. of bitstreams: 1 ntu-108-R06B48001-1.pdf: 2227254 bytes, checksum: 0d3b8c7f9e3576e1857334a88c5af447 (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 口試委員會審定書 ...#
誌謝 ...i 中文摘要 ...ii ABSTRACT ...iii CONTENTS ...iv LIST OF FIGURES ...vi LIST OF TABLES ...vii Chapter 1 Introduction 1 1.1 Drug development ...4 1.2 Adverse effects and withdrawn drugs ...4 1.3 Rules of drug design ...7 1.4 Chemical properties in drug design ...8 1.5 Adverse effects and protein targets ...9 1.6 Motivation and aims ...10 Chapter 2 Methods 11 2.1 Data Collection for chemical properties of WDs and MDs ...11 2.2 Analysis of the properties of WDs and MDs ...13 2.3 Investigation of a simple rule for distinguishing WDs and MDs ...13 2.4 Prediction of WDs and MDs ...15 2.5 Analyzing the protein targets of MDs and WDs ...18 2.6 Analyzing ARPs and NARPs ...19 2.7 Prediction of ARPs and NARPs ...20 Chapter 3 Results 21 3.1 Analysis of the properties of WDs and MDs ...21 3.2 Investigation of a simple rule for distinguishing WDs and MDs ...28 3.3 Prediction of WDs and MDs ...30 3.3.1 F1 score for the validation set and test set ...30 3.3.2 Feature importance for random forest ...31 3.3.3 A case prediction ...32 3.4 Analyzing the protein targets of MDs and WDs ...34 3.5 Analysis of the properties of NARPs and ARPs ...37 3.6 Prediction of ARPs and NARPs ...39 3.6.1 F1 score on the of validation set and test set ...39 3.6.2 Feature importance for random forest ...41 Chapter 4 Discussions 43 4.1 Analysis of the properties of WDs and MDs and possible reasons for the differences between WDs and MDs ...43 4.2 Rule of Five, Ghose Filter and MDDR-Like Rule of WDs and MDs ...46 4.3 A simple rule for distinguishing WDs and MDs ...46 4.4 Prediction of WDs and MDs ...48 4.5 Analyzing the protein targets of MDs and WDs ...48 4.6 Prediction of ARPs and NARPs ...50 4.7 Recommendations for drug development ...50 Chapter 5 Conclusions ...54 REFERENCE ...55 | |
dc.language.iso | en | |
dc.title | 仍上市及下市藥物與其蛋白標的之機器學習研究以預測藥物引起的不良反應 | zh_TW |
dc.title | A study on market and withdrawn drugs and their protein targets to predict adverse effect by machine learning | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 梁國淦(Kuo-Kan Liang),潘思樺(Szu-Hua Pan) | |
dc.subject.keyword | 機器學習,藥學,下市藥物,蛋白質標的,不良反應, | zh_TW |
dc.subject.keyword | Machine learning,pharmacy,withdrawn drugs,targets,adverse effects, | en |
dc.relation.page | 62 | |
dc.identifier.doi | 10.6342/NTU201901353 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-07-23 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 基因體與系統生物學學位學程 | zh_TW |
顯示於系所單位: | 基因體與系統生物學學位學程 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 2.18 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。